Rapport Therapeutics Stock (NASDAQ: RAPP)

Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

Stock Movers

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MLNK

MVST

NCMI

NCNO

NMAX

RAPP

TSLA

nCino Posts Weak Earnings, Joins Tesla And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

Sportsman'sSaratoga,Springs,,Utah,,Usa,-,Nov,30,,2024:,Sportsman's,Warehouse

AEHL

AGMH

BIAF

DGLY

GRFS

QUAD

RSLS

SAMG

SBFM

SPWH

STSS

SYRA

Why Sportsman&#39;s Warehouse Shares Are Trading Higher By Around 39%; Here Are 20 Stocks Moving Premarket

Super Micro Computer, Bakkt Holdings, MARA Holdings, Microstrategy, And Tesla Inc: Why These 5 Stocks Are On Investors' Radars Today

CHWY

HUMA

NYXH

ORKA

PPTA

RGNX

ZYBT

Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics Inc

Press Releases

Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November

Earnings

Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update

Health Care

Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting

Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures

Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Management

Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development

Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting

Alumis

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Arvinas

Atea Pharmaceuticals, Inc. - common stock

Atea Pharmaceuticals

Cormedix

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals

GH Research

Maze Therapeutics

MBX Biosciences

Omeros

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Septerna

SIGA Technologies

SNDL

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharma

Third Harmonic Bio

Tilray Brands

Tvardi Therapeutics

Zevra Therapeutics

Zhengye Biotechnology Holding Limited - Ordinary Shares

Zhengye Biotechnology

JMP Securities

Jones Trading

Stifel

Jefferies

Comments

Rapport Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell